# RAG answer evaluation

Generator: gemini-3.8-flash via OpenRouter · Judge: qwen/qwen3.8-27b (openrouter, temperature 0) · 4 questions · 3 run(s) each · 2026-10-17 18:31

Rubric dimensions are scored 1 (Poor) to 4 (Excellent); RAGAS dimensions and citation validity 0–1.

## Scores

| Question | Run | Mode | Faithfulness | Answer relevance | Context relevance | Biological plausibility | Literature support | Consistency | Clinical readability | Reproducibility | Citation validity |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Q1 | 1 | compare | 0.833 | 1.0 | 1.0 | 3 | 3 | 4 | 3 | 3 | 1.0 |
| Q1 | 2 | compare | 0.857 | 1.0 | 1.0 | 3 | 3 | 3 | 3 | 3 | 1.0 |
| Q1 | 3 | compare | 0.75 | 1.0 | 0.754 | 3 | 3 | 3 | 3 | 3 | 1.0 |
| Q2 | 1 | compare | 0.885 | 1.0 | 0.629 | 3 | 3 | 4 | 3 | 3 | 1.0 |
| Q2 | 2 | compare | 0.882 | 1.0 | 0.829 | 3 | 3 | 3 | 3 | 3 | 1.0 |
| Q2 | 3 | compare | 0.763 | 1.0 | 0.743 | 3 | 3 | 3 | 3 | 3 | 1.0 |
| Q3 | 1 | compare | 0.853 | 1.0 | 0.586 | 3 | 3 | 3 | 4 | 3 | 1.0 |
| Q3 | 2 | compare | 0.833 | 0.75 | 0.517 | 3 | 3 | 3 | 3 | 3 | 1.0 |
| Q3 | 3 | compare | 0.853 | 0.75 | 0.655 | 3 | 3 | 3 | 3 | 3 | 1.0 |
| Q4 | 1 | compare | 0.8 | 1.0 | 0.754 | 3 | 3 | 3 | 3 | 3 | 1.0 |
| Q4 | 2 | compare | 0.8 | 1.0 | 0.797 | 3 | 3 | 3 | 3 | 3 | 1.0 |
| Q4 | 3 | compare | 0.826 | 1.0 | 0.812 | 3 | 3 | 3 | 3 | 3 | 1.0 |

## Mean per dimension

| Dimension | Mean | n |
| --- | --- | --- |
| Faithfulness | 0.83 | 12 |
| Answer relevance | 0.96 | 12 |
| Context relevance | 0.76 | 12 |
| Biological plausibility | 3.00 | 12 |
| Literature support | 3.00 | 12 |
| Consistency | 3.17 | 12 |
| Clinical readability | 3.08 | 12 |
| Reproducibility | 3.00 | 12 |
| Citation validity | 1.00 | 12 |

## Justifications

| Question | Run | Dimension | Score | Justification |
| --- | --- | --- | --- | --- |
| Q1 | 1 | Faithfulness | 0.833 | 18/18 claims supported or partially supported. Unsupported: none |
| Q1 | 1 | Answer relevance | 1.0 | The answer directly addresses why the signatures disagree by combining the observed statistical discordance, the disjoint gene composition, the distinct pathway biology, and the shared grade-axis interpretation, while also noting missing evidence. |
| Q1 | 1 | Context relevance | 1.0 | 69 of 69 retrieved records judged relevant. |
| Q1 | 1 | Biological plausibility | 3 | The explanation is biologically plausible: disjoint gene sets, distinct pathway enrichments, and a shared grade axis are consistent with known glioma heterogeneity. Minor issues include overgeneralizing some signature biology (e.g., Glyco and Stemness) beyond what the retrieved records explicitly establish. |
| Q1 | 1 | Literature support | 3 | The answer cites relevant PubMed evidence, especially PMID_42739233_chunk3 for the grade-axis interpretation and signature-specific papers for biological context. It is well supported, though some biological characterizations rely more on derived pathway records than on direct literature. |
| Q1 | 1 | Consistency | 4 | The reasoning is internally coherent: it moves from observed statistical disagreement to gene/pathway differences, then to a plausible shared-axis explanation, and finally to missing evidence. The claims are logically structured and do not contradict the retrieved records. |
| Q1 | 1 | Clinical readability | 3 | The answer is clear and interpretable, with a useful summary and explicit evidence gaps. It is somewhat dense with statistics and gene lists, which may reduce readability for a purely clinical audience. |
| Q1 | 1 | Reproducibility | 3 | All three runs consistently concluded that the signatures use disjoint gene sets to capture distinct biology while sharing an underlying glioma grade axis, and they repeated the same individual log-rank p-values, zero gene overlap, and concordance ranges (ARI 0.1413–0.5142, Jaccard 0.5253–0.7525, r 0.2966–0.8181). Variability appeared in pathway p-values/IDs for Diffuse, the strength of support for the grade-axis explanation, and added details such as Hypoxia’s low concordance and a contradictory Diffuse multivariate claim. (Mean Jaccard of cited IDs across runs: 0.696.) |
| Q1 | 2 | Faithfulness | 0.857 | 21/21 claims supported or partially supported. Unsupported: none |
| Q1 | 2 | Answer relevance | 1.0 | The answer directly addresses why the signatures disagree by combining the observed statistical discordance, signature composition, pathway differences, plausible biological explanations, and limitations. It is comprehensive rather than padded. |
| Q1 | 2 | Context relevance | 1.0 | 69 of 69 retrieved records judged relevant. |
| Q1 | 2 | Biological plausibility | 3 | The core explanation is biologically plausible: disjoint gene sets, distinct pathways, and a shared grade/malignancy axis are consistent with known glioma biology. Minor issues include over-specific wording for Glyco and causal framing that is not fully established. |
| Q1 | 2 | Literature support | 3 | The answer is well supported by retrieved statistical, derived, pathway, and PubMed records, especially PMID_42739233_chunk3 for the grade-axis/random-null point. Some literature chunks are sparse, and a few interpretive claims exceed what the cited literature directly proves. |
| Q1 | 2 | Consistency | 3 | The reasoning is mostly coherent and logically structured, but it uses causal language such as 'leads to' and 'because' for claims that are better labelled as hypotheses. It also labels some interpretive claims as Supported when they are only partially supported. |
| Q1 | 2 | Clinical readability | 3 | The answer is clear and well organized, with a useful bottom line. It is somewhat technical because of ARI, Jaccard, p-values, and gene/pathway names, but still interpretable for a clinically informed reader. |
| Q1 | 2 | Reproducibility | 3 | All three runs consistently concluded that the signatures use disjoint gene sets to capture distinct biology while sharing an underlying glioma grade axis, and they repeated the same individual log-rank p-values, zero gene overlap, and concordance ranges (ARI 0.1413–0.5142, Jaccard 0.5253–0.7525, r 0.2966–0.8181). Variability appeared in pathway p-values/IDs for Diffuse, the strength of support for the grade-axis explanation, and added details such as Hypoxia’s low concordance and a contradictory Diffuse multivariate claim. (Mean Jaccard of cited IDs across runs: 0.696.) |
| Q1 | 3 | Faithfulness | 0.75 | 17/18 claims supported or partially supported. Unsupported: The Diffuse model was reported to predict survival independently of histopathological grade and IDH status in multivariate models. |
| Q1 | 3 | Answer relevance | 1.0 | The answer directly addresses why the signatures disagree by quantifying individual survival significance, pairwise discordance, gene and pathway separation, and the grade-axis caveat. |
| Q1 | 3 | Context relevance | 0.754 | 52 of 69 retrieved records judged relevant. |
| Q1 | 3 | Biological plausibility | 3 | The biological framing is mostly consistent with glioma biology, but the Hypoxia description is slightly imprecise because UBB is ubiquitin rather than a proteasome subunit. |
| Q1 | 3 | Literature support | 3 | The answer uses relevant statistical, pathway, GO, and PubMed evidence, but it overstates the grade-axis audit and cites an unsupported independence claim for the Diffuse signature. |
| Q1 | 3 | Consistency | 3 | The structure is coherent and the numerical claims are internally consistent, but causal wording and one unsupported literature claim reduce scientific consistency. |
| Q1 | 3 | Clinical readability | 3 | The answer is clear and well organized, though it is somewhat technical and dense for a purely clinical audience. |
| Q1 | 3 | Reproducibility | 3 | All three runs consistently concluded that the signatures use disjoint gene sets to capture distinct biology while sharing an underlying glioma grade axis, and they repeated the same individual log-rank p-values, zero gene overlap, and concordance ranges (ARI 0.1413–0.5142, Jaccard 0.5253–0.7525, r 0.2966–0.8181). Variability appeared in pathway p-values/IDs for Diffuse, the strength of support for the grade-axis explanation, and added details such as Hypoxia’s low concordance and a contradictory Diffuse multivariate claim. (Mean Jaccard of cited IDs across runs: 0.696.) |
| Q2 | 1 | Faithfulness | 0.885 | 26/26 claims supported or partially supported. Unsupported: none |
| Q2 | 1 | Answer relevance | 1.0 | The answer directly compares the two requested pairs, reports the relevant agreement statistics, and explains the difference using gene composition, pathway overlap, and literature-supported stemness links while noting limitations. |
| Q2 | 1 | Context relevance | 0.629 | 22 of 35 retrieved records judged relevant. |
| Q2 | 1 | Biological plausibility | 3 | The explanation is biologically coherent: Glyco has stemness-related genes and pathway overlap with Stemness, while Hypoxia is proteasome/ubiquitin-centric. It is plausible but not fully established by the retrieved evidence. |
| Q2 | 1 | Literature support | 3 | The answer cites relevant PubMed evidence for TNFRSF12A, hypoxia-stemness crosstalk, and POU5F1/Oct-4, plus database annotations. Some claims, such as CHI3L1/SERPING1 affecting hypoxia-induced stemness, are only partially supported by the visible chunk. |
| Q2 | 1 | Consistency | 4 | The reasoning is internally consistent: it separates observed statistics from biological interpretation, labels hypotheses appropriately, and notes that gene sharing is not the explanation. |
| Q2 | 1 | Clinical readability | 3 | The answer is clear and structured, but the density of gene names, pathway IDs, and statistical values makes it less immediately concise for a clinical reader. |
| Q2 | 1 | Reproducibility | 3 | All runs consistently report the same ARI, Jaccard, Pearson, log-rank p-values, gene lists, zero gene overlap, pathway overlaps, and conclusion that Glyco shares stemness-related biology while Hypoxia is proteasome-centric. Variability is limited to minor wording, added Jaccard values, and occasional extra evidence such as E2F1 hypoxia response. (Mean Jaccard of cited IDs across runs: 0.853.) |
| Q2 | 2 | Faithfulness | 0.882 | 17/17 claims supported or partially supported. Unsupported: none |
| Q2 | 2 | Answer relevance | 1.0 | The answer directly compares the two pairs with concordance statistics and explains the difference using gene composition, pathway overlap, and literature, while flagging hypotheses and contradictory evidence. |
| Q2 | 2 | Context relevance | 0.829 | 29 of 35 retrieved records judged relevant. |
| Q2 | 2 | Biological plausibility | 3 | Mostly plausible: Glyco stemness links and the Hypoxia proteasome/ubiquitin composition are supported, but the SERPING1 claim and causal independence are overextended. |
| Q2 | 2 | Literature support | 3 | The answer uses relevant PubMed, GO, Reactome, STRING, and statistical records, but some gene-specific claims lack direct retrieved support. |
| Q2 | 2 | Consistency | 3 | The reasoning is coherent and acknowledges contradictory hypoxia-stemness literature, though the proteasomal explanation remains inferential. |
| Q2 | 2 | Clinical readability | 3 | The structure is clear and clinically interpretable, but the technical detail makes it less concise than an ideal clinical summary. |
| Q2 | 2 | Reproducibility | 3 | All runs consistently report the same ARI, Jaccard, Pearson, log-rank p-values, gene lists, zero gene overlap, pathway overlaps, and conclusion that Glyco shares stemness-related biology while Hypoxia is proteasome-centric. Variability is limited to minor wording, added Jaccard values, and occasional extra evidence such as E2F1 hypoxia response. (Mean Jaccard of cited IDs across runs: 0.853.) |
| Q2 | 3 | Faithfulness | 0.763 | 19/19 claims supported or partially supported. Unsupported: none |
| Q2 | 3 | Answer relevance | 1.0 | The answer directly addresses the question by comparing the two pair statistics, explaining gene and functional differences, and offering evidence-based hypotheses for why Glyco-Stemness concordance is higher than Hypoxia-Stemness concordance. |
| Q2 | 3 | Context relevance | 0.743 | 26 of 35 retrieved records judged relevant. |
| Q2 | 3 | Biological plausibility | 3 | The biological reasoning is mostly plausible: Glyco has stemness-associated genes, Stemness is transcriptional/cell-cycle oriented, and Hypoxia is proteasome/ubiquitin-centric. Minor issues include the CHI3L1 claim and proteasome-dependent degradation wording, which are not fully explicit in the retrieved evidence. |
| Q2 | 3 | Literature support | 3 | The answer cites relevant PubMed, MSigDB, Reactome, GO, and statistical records. Support is good but incomplete for a few interpretive claims, especially CHI3L1 and the causal final explanation. |
| Q2 | 3 | Consistency | 3 | The answer is coherent and appropriately labels several mechanistic statements as plausible hypotheses. It slightly overstates causality in the final sentence, which prevents a top score. |
| Q2 | 3 | Clinical readability | 3 | The structure is clear and clinically interpretable, with statistics, gene lists, and biological interpretation separated. It is somewhat technical but still readable. |
| Q2 | 3 | Reproducibility | 3 | All runs consistently report the same ARI, Jaccard, Pearson, log-rank p-values, gene lists, zero gene overlap, pathway overlaps, and conclusion that Glyco shares stemness-related biology while Hypoxia is proteasome-centric. Variability is limited to minor wording, added Jaccard values, and occasional extra evidence such as E2F1 hypoxia response. (Mean Jaccard of cited IDs across runs: 0.853.) |
| Q3 | 1 | Faithfulness | 0.853 | 17/17 claims supported or partially supported. Unsupported: none |
| Q3 | 1 | Answer relevance | 1.0 | The answer directly addresses why the signatures largely agree by reporting the concordance statistics, explaining the distinct gene/pathway composition, and interpreting the residual disagreement with appropriately labelled hypotheses. |
| Q3 | 1 | Context relevance | 0.586 | 17 of 29 retrieved records judged relevant. |
| Q3 | 1 | Biological plausibility | 3 | The explanation is biologically plausible: cell-cycle/DNA-integrity signatures and glycosylation/cytokine-related signatures can both mark aggressive glioma, but the retrieved evidence does not directly prove co-occurrence or shared downstream biology. |
| Q3 | 1 | Literature support | 3 | The answer cites relevant PubMed chunks for glycosylation-related glioma prognostic models and prognostic biomarker context, but the literature support is indirect for the specific claim that the two signatures agree because of shared aggressive-glioma hallmarks. |
| Q3 | 1 | Consistency | 3 | The reasoning is mostly coherent, but the final causal statement 'because cell cycle disruption and glycosylation-associated changes co-occur' is stronger than the retrieved evidence supports and should be framed as a hypothesis. |
| Q3 | 1 | Clinical readability | 4 | The answer is clearly structured, uses concrete statistics and gene/pathway examples, and is easy for a clinical reader to interpret. |
| Q3 | 1 | Reproducibility | 3 | All runs consistently report the same core statistics (r = 0.8181, Jaccard = 0.7437, ARI = 0.4978, 336/336 cohorts, log-rank p-values), the same non-overlapping gene lists, and the same conclusion that cell-cycle/DNA-repair and glycosylation/immune programs co-occur in aggressive gliomas. They vary mainly in emphasis and detail: Run 3 adds specific shared MSigDB sets and frames convergence as supported, while Runs 1-2 are more cautious and include slightly different pathway annotations. Thus the outputs are mostly reproducible but not perfectly identical. (Mean Jaccard of cited IDs across runs: 0.847.) |
| Q3 | 2 | Faithfulness | 0.833 | 15/15 claims supported or partially supported. Unsupported: none |
| Q3 | 2 | Answer relevance | 0.75 | The answer directly addresses the question by reporting concordance statistics, contrasting gene/pathway biology, and proposing a plausible shared-aggressiveness explanation, but the core mechanistic reason remains hypothesis-level and is limited by missing covariates. |
| Q3 | 2 | Context relevance | 0.517 | 15 of 29 retrieved records judged relevant. |
| Q3 | 2 | Biological plausibility | 3 | The contrast between cell-cycle/DNA-repair biology and glycosylation/immune biology is plausible and supported by pathway and literature records. However, the claim that these processes co-occur to explain concordance is not directly demonstrated. |
| Q3 | 2 | Literature support | 3 | The answer cites relevant PubMed chunks for WEE1, CHI3L1, and glycosylation-related glioma prognostic models. The support is relevant but incomplete because the chunks do not directly establish shared biology or co-occurrence in the same patients. |
| Q3 | 2 | Consistency | 3 | The reasoning is generally coherent and separates observed statistics from interpretation. Some interpretive statements are labeled more strongly than the evidence warrants, and the 25% non-overlap is a derived approximation. |
| Q3 | 2 | Clinical readability | 3 | The answer is well structured and understandable, with a clear final summary. It is somewhat dense with statistics, gene lists, and pathway details, which slightly reduces immediate clinical readability. |
| Q3 | 2 | Reproducibility | 3 | All runs consistently report the same core statistics (r = 0.8181, Jaccard = 0.7437, ARI = 0.4978, 336/336 cohorts, log-rank p-values), the same non-overlapping gene lists, and the same conclusion that cell-cycle/DNA-repair and glycosylation/immune programs co-occur in aggressive gliomas. They vary mainly in emphasis and detail: Run 3 adds specific shared MSigDB sets and frames convergence as supported, while Runs 1-2 are more cautious and include slightly different pathway annotations. Thus the outputs are mostly reproducible but not perfectly identical. (Mean Jaccard of cited IDs across runs: 0.847.) |
| Q3 | 3 | Faithfulness | 0.853 | 17/17 claims supported or partially supported. Unsupported: none |
| Q3 | 3 | Answer relevance | 0.75 | The answer directly addresses why the signatures agree by citing concordance statistics, non-overlapping genes, and shared gene-set annotations. It is slightly less than fully direct because the bottom-line causal explanation and the ~25% patient fraction are not fully established by the retrieved evidence. |
| Q3 | 3 | Context relevance | 0.655 | 19 of 29 retrieved records judged relevant. |
| Q3 | 3 | Biological plausibility | 3 | The explanation is mostly biologically plausible, linking cell-cycle/DNA-repair biology in Diffuse with glycosylation/immune biology in Glyco and shared oncogenic gene sets. Minor issues include relying on general knowledge for WEE1 as a kinase and an imprecise ~25% patient estimate. |
| Q3 | 3 | Literature support | 3 | The answer cites relevant statistical, derived, Reactome, GO, MSigDB, and PubMed records. However, the PubMed chunks are limited and do not directly establish that the two programs co-occur causally in aggressive glioma. |
| Q3 | 3 | Consistency | 3 | The reasoning is generally coherent and well structured, but the bottom line uses causal 'because' language after earlier labeling the mechanism as a plausible hypothesis, and the Jaccard-to-25% inference is questionable. |
| Q3 | 3 | Clinical readability | 3 | The answer is clear, organized, and interpretable for a clinical or translational audience, though it is somewhat technical and includes a few inferential leaps. |
| Q3 | 3 | Reproducibility | 3 | All runs consistently report the same core statistics (r = 0.8181, Jaccard = 0.7437, ARI = 0.4978, 336/336 cohorts, log-rank p-values), the same non-overlapping gene lists, and the same conclusion that cell-cycle/DNA-repair and glycosylation/immune programs co-occur in aggressive gliomas. They vary mainly in emphasis and detail: Run 3 adds specific shared MSigDB sets and frames convergence as supported, while Runs 1-2 are more cautious and include slightly different pathway annotations. Thus the outputs are mostly reproducible but not perfectly identical. (Mean Jaccard of cited IDs across runs: 0.847.) |
| Q4 | 1 | Faithfulness | 0.8 | 10/10 claims supported or partially supported. Unsupported: none |
| Q4 | 1 | Answer relevance | 1.0 | The answer directly addresses the weaker concordance of Hypoxia with statistical pair metrics, gene/pathway composition, zero overlap, and a validation audit, while flagging hypotheses and missing data. |
| Q4 | 1 | Context relevance | 0.754 | 52 of 69 retrieved records judged relevant. |
| Q4 | 1 | Biological plausibility | 3 | The proteasome/ubiquitin composition and distinct pathway focus are biologically plausible explanations for different risk stratification. The phrase proteasome-mediated HIF-1alpha proline hydroxylation is imprecise because the retrieved pathway is oxygen-dependent hydroxylation, not explicitly proteasome-mediated. |
| Q4 | 1 | Literature support | 3 | The answer cites a directly relevant audit for Hypoxia performance and hypoxia-stemness literature for POU5F1. Support is good but incomplete for the broader causal explanation of disagreement. |
| Q4 | 1 | Consistency | 3 | The reasoning is mostly coherent, moving from concordance statistics to composition, overlap, and validation. It slightly overstates causality in the bottom line and labels MSigDB overlap as contradictory when it is better described as a nuance. |
| Q4 | 1 | Clinical readability | 3 | The answer is structured, uses concrete metrics, and separates supported points from hypotheses. It remains technical but is interpretable for a clinical genomics audience. |
| Q4 | 1 | Reproducibility | 3 | All runs consistently report the same concordance statistics (ARI 0.1413-0.1882, Jaccard 0.5253-0.5596, r 0.2966-0.5124; non-Hypoxia ARI 0.3759-0.5142), the same Hypoxia proteasome/ubiquitin gene set, zero gene/pathway overlap, and the same core conclusion. They vary mainly in explanatory emphasis and cited counter-evidence, such as MSigDB overlap, hypoxia-stemness crosstalk, and pathway descriptions for the other signatures. (Mean Jaccard of cited IDs across runs: 0.681.) |
| Q4 | 2 | Faithfulness | 0.8 | 25/25 claims supported or partially supported. Unsupported: none |
| Q4 | 2 | Answer relevance | 1.0 | The answer directly addresses why Hypoxia disagrees by quantifying weaker concordance, contrasting gene/pathway composition, and offering evidence-based hypotheses. Minor causal overstatement does not reduce its directness or completeness. |
| Q4 | 2 | Context relevance | 0.797 | 55 of 69 retrieved records judged relevant. |
| Q4 | 2 | Biological plausibility | 3 | The explanation is mostly biologically coherent: a narrow proteasome/HIF-1α/NOTCH4 signature can stratify differently from senescence, caspase, stemness, and glyco/immune signatures, and hypoxia-stemness crosstalk is acknowledged. Minor issues include calling HIF-1α hydroxylation 'proteasome-mediated degradation' and conflating pyroptosis with apoptosis. |
| Q4 | 2 | Literature support | 3 | Relevant PubMed records support hypoxia-stemness and the external audit of a PSMB6-containing hypoxia model. However, several biological characterizations rely mainly on database annotations rather than explicit literature support. |
| Q4 | 2 | Consistency | 3 | The answer is logically structured and separates supported observations from hypotheses. The main inconsistency is the bottom-line causal 'because' language despite earlier stating that clinical confounding is not established. |
| Q4 | 2 | Clinical readability | 3 | The answer is clear and clinically interpretable, with concrete metrics, gene lists, pathway examples, and labelled uncertainty. It is somewhat dense but remains understandable. |
| Q4 | 2 | Reproducibility | 3 | All runs consistently report the same concordance statistics (ARI 0.1413-0.1882, Jaccard 0.5253-0.5596, r 0.2966-0.5124; non-Hypoxia ARI 0.3759-0.5142), the same Hypoxia proteasome/ubiquitin gene set, zero gene/pathway overlap, and the same core conclusion. They vary mainly in explanatory emphasis and cited counter-evidence, such as MSigDB overlap, hypoxia-stemness crosstalk, and pathway descriptions for the other signatures. (Mean Jaccard of cited IDs across runs: 0.681.) |
| Q4 | 3 | Faithfulness | 0.826 | 23/23 claims supported or partially supported. Unsupported: none |
| Q4 | 3 | Answer relevance | 1.0 | The answer directly addresses the question by quantifying weaker Hypoxia concordance, showing gene/pathway isolation, and linking this to a distinct biological axis and weaker subgroup discrimination. It also notes limitations, making it complete and on-topic. |
| Q4 | 3 | Context relevance | 0.812 | 56 of 69 retrieved records judged relevant. |
| Q4 | 3 | Biological plausibility | 3 | The core explanation that a narrow proteasome/ubiquitin signature with no shared genes or top pathways can define a different risk axis is biologically plausible. However, calling the cited HIF/NOTCH pathways 'proteasome-mediated' and characterizing Glyco as immune/glycoprotein biology is imprecise. |
| Q4 | 3 | Literature support | 3 | Key statistical and discrimination claims are tied to retrieved PubMed and statistical records. Some biological characterizations rely on indirect gene/pathway evidence rather than direct literature support. |
| Q4 | 3 | Consistency | 3 | The reasoning is mostly coherent and logically organized. It is weakened by causal wording ('because', 'leads to') and by labeling an interpretive alignment as Supported. |
| Q4 | 3 | Clinical readability | 3 | The answer is clearly structured and uses concrete metrics, making it interpretable. It is somewhat dense with IDs and technical terms, but still clinically readable. |
| Q4 | 3 | Reproducibility | 3 | All runs consistently report the same concordance statistics (ARI 0.1413-0.1882, Jaccard 0.5253-0.5596, r 0.2966-0.5124; non-Hypoxia ARI 0.3759-0.5142), the same Hypoxia proteasome/ubiquitin gene set, zero gene/pathway overlap, and the same core conclusion. They vary mainly in explanatory emphasis and cited counter-evidence, such as MSigDB overlap, hypoxia-stemness crosstalk, and pathway descriptions for the other signatures. (Mean Jaccard of cited IDs across runs: 0.681.) |

## Questions

- **Q1**: Why do different glioma signatures show inconsistent prognostic outcomes?
- **Q2**: Why do Glyco and Stemness classify patients more similarly than Hypoxia and Stemness?
- **Q3**: Why do the Diffuse and Glyco signatures largely agree on which patients are high risk?
- **Q4**: Why does the Hypoxia signature disagree with the other four signatures, showing much weaker concordance in patient risk stratification?
